plasmaMATCH is a multi-centre phase IIa umbrella trial platform consisting of a ctDNA screening component and a therapeutic component. plasmaMATCH aims to assess whether ctDNA screening can be used to detect patients with targetable mutations, and will assess the safety and activity of the targeted treatments in patients with targetable mutations identified at ctDNA screening.